Clinical trial
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe…
NCT00482248 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00482248 |
|---|---|
| Title | Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma |
| Official title | An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study |
| Lead sponsor | Novartis, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 132 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Jun 5, 2007 |
| Last update posted | Nov 18, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: